Etuvetidigene Autotemcel for the Treatment of Wiskott-Aldrich Syndrome.

Etuvetidigene autotemcel achieves a 96% survival rate over five years in children with Wiskott-Aldrich syndrome, significantly reducing severe infections and bleeding events.

• Why it matters: Wiskott-Aldrich syndrome is a rare, life-threatening immunodeficiency with limited treatment options, highlighting the need for effective, durable therapies to improve patient outcomes.
• What they did: Researchers combined data from two clinical trials and an expanded-access program involving 27 participants who received a single infusion of etu-cel, a gene therapy using lentiviral vectors to correct WAS gene mutations.
• The result: The therapy led to a substantial decrease in infection and bleeding rates, enabling sustained clinical benefits and demonstrating safety with no evidence of insertional oncogenesis, supporting its potential as a long-term treatment.